KBC Group NV Sells 219,241 Shares of Henry Schein, Inc. (NASDAQ:HSIC)

KBC Group NV trimmed its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 49.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 225,371 shares of the company’s stock after selling 219,241 shares during the period. KBC Group NV owned 0.18% of Henry Schein worth $16,429,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. UniSuper Management Pty Ltd lifted its position in Henry Schein by 611.8% during the 1st quarter. UniSuper Management Pty Ltd now owns 13,695 shares of the company’s stock valued at $1,034,000 after acquiring an additional 11,771 shares during the period. Thompson Siegel & Walmsley LLC purchased a new position in shares of Henry Schein during the second quarter valued at approximately $46,683,000. Vanguard Group Inc. boosted its position in shares of Henry Schein by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 15,432,001 shares of the company’s stock worth $1,165,425,000 after purchasing an additional 260,537 shares in the last quarter. SG Americas Securities LLC boosted its position in shares of Henry Schein by 1,622.3% in the 3rd quarter. SG Americas Securities LLC now owns 458,828 shares of the company’s stock worth $33,449,000 after purchasing an additional 432,187 shares in the last quarter. Finally, Sei Investments Co. grew its stake in shares of Henry Schein by 8.0% in the 2nd quarter. Sei Investments Co. now owns 420,957 shares of the company’s stock worth $26,983,000 after buying an additional 31,168 shares during the last quarter. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Insider Buying and Selling

In other Henry Schein news, SVP Lorelei Mcglynn sold 21,035 shares of the stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $69.30, for a total transaction of $1,457,725.50. Following the completion of the sale, the senior vice president now directly owns 71,833 shares of the company’s stock, valued at $4,978,026.90. This trade represents a 22.65 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.14% of the stock is currently owned by insiders.

Henry Schein Price Performance

Shares of HSIC opened at $68.76 on Friday. Henry Schein, Inc. has a 1-year low of $63.67 and a 1-year high of $82.63. The firm has a fifty day simple moving average of $70.30 and a two-hundred day simple moving average of $69.57. The company has a current ratio of 1.42, a quick ratio of 0.82 and a debt-to-equity ratio of 0.46. The firm has a market cap of $8.57 billion, a PE ratio of 28.30, a P/E/G ratio of 1.94 and a beta of 0.87.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, November 5th. The company reported $1.22 earnings per share for the quarter, topping the consensus estimate of $1.17 by $0.05. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The business had revenue of $3.17 billion for the quarter, compared to the consensus estimate of $3.24 billion. During the same period last year, the firm earned $1.32 earnings per share. The company’s quarterly revenue was up .4% on a year-over-year basis. On average, equities analysts anticipate that Henry Schein, Inc. will post 4.78 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Baird R W raised Henry Schein from a “hold” rating to a “strong-buy” rating in a report on Monday, July 22nd. JPMorgan Chase & Co. dropped their price target on shares of Henry Schein from $88.00 to $80.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. StockNews.com upgraded shares of Henry Schein from a “sell” rating to a “hold” rating in a research note on Thursday, November 7th. UBS Group dropped their target price on shares of Henry Schein from $75.00 to $72.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. Finally, Evercore ISI raised their price target on shares of Henry Schein from $70.00 to $74.00 and gave the company an “in-line” rating in a research report on Tuesday, October 8th. Six equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Henry Schein currently has a consensus rating of “Moderate Buy” and a consensus target price of $78.89.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.